Zydus completes enrollment in three Phase 3 trials of Saroglitazar Magnesium in NASH

Zydus Cadila announced announced that it has completed enrolment in EVIDENCES 11,EVIDENCES 111and EVIDENCES V Phase 3 clinical trials of Saroglitazar Mg for treating Non-Alcoholic SteatoHepatitis(NASH). Patients with NASH have been enrolled in these trials across clinical sites in India and Mexico.

NASH is a progressive disease of the liver and a significant unmet medical need. Starting with fat accumulation in liver, this condition can progress to cirrhosis and liver failure. NASH ranks as one of the major causes of cirrhosis, behind hepatitis C and alcoholic liver disease. Liver transplantation is the only option for managing advanced cirrhosis with liver failure. There are currently no treatments available for the treatment of NASH.

Powered by Capital Market - Live News